SHINE Medical Technologies Therapeutics division has made its first commercial sale of lutetium-177, a therapeutic isotope in demand by clinical trial sponsors, the company announced recently.

“This milestone is really exciting, as Lu-177 is effectively a smart bomb for certain types of cancer,” SHINE CEO Greg Piefer said in a statement. “We’re enthusiastic about bringing our core competencies to this market and believe we’ll play a major role in ensuring patients worldwide will have access to this very important isotope.”

According to a release, Lu-177 is being used in numerous clinical trials to treat a range of cancers. It was developed with SHINE’s partners, the Institute of Organic Chemistry and Biochemistry and the Nuclear Physics Institute of the Czech Academy of Sciences.

SHINE is currently producing Lu-177 in its Building One facility.